title: Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.
abstract: Recently, there has been an increasing concern that atypical antipsychotics as well as typical ones may cause detrimental effects on cognitive function. Supporting evidence comes from many preclinical studies demonstrating that long-term administration of haloperidol, risperidone, and ziprasidone reduced choline acetyltransferase (ChAT) expression in rat hippocampus (HIP). However, to the best of our knowledge, no studies have examined the effects of amisulpride on ChAT expression in rats. Therefore, the aim of this study was to investigate the effects of acute and chronic administration of amisulpride, haloperidol, and risperidone on ChAT expression in the rat prefrontal cortex (PFC) and HIP. Animals received daily intraperitoneal (i.p.) injections of amisulpride (5 or 100mg/kg), haloperidol (1 or 2mg/kg), risperidone (1 or 2mg/kg) or vehicle for 7 or 45 days. One day after the last injection, rats were sacrificed. ChAT immunoreactivity was assessed with immunofluorescence staining. Target areas of brain were PFC and HIP (CA1, CA3 and DG). The short-term administration of haloperidol and risperidone produced significant decrease of ChAT immunoreactivity in the PFC and HIP compared to vehicle whereas amisulpride had no effects on ChAT immunoreactivity in the PFC and HIP. In long-term study, haloperidol and risperidone decreased ChAT-positive cells and/or fiber pixel density in the PFC and HIP whereas amisulpride decreased ChAT-positive cells in the PFC and had no effects on fiber pixel density of ChAT in the HIP. The results suggest that both short-term and long-term administration of haloperidol and risperidone, and long-term administration of amisulpride may produce detrimental effects on cognitive function by reducing ChAT expression in the PFC and/or HIP.
authors.affiliation: Department of Psychiatry, Chonbuk National University Medical School & Institute for Medical Sciences, Jeonju 561-756, South Korea.
authors.forename: Guang-Biao
authors.initials: GB
authors.lastname: Huang
authors.forename: Tong
authors.initials: T
authors.lastname: Zhao
authors.forename: Chun-Rong
authors.initials: CR
authors.lastname: Li
authors.forename: Zhi-Yan
authors.initials: ZY
authors.lastname: Sui
authors.forename: Nam-In
authors.initials: NI
authors.lastname: Kang
authors.forename: Eui-Hyeog
authors.initials: EH
authors.lastname: Han
authors.forename: Young-Chul
authors.initials: YC
authors.lastname: Chung
mesh_terms: D000077582:Amisulpride; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000009:adverse effects*; D006624:Hippocampus / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000009:adverse effects*; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride; D002795:Choline O-Acetyltransferase; D006220:Haloperidol; D018967:Risperidone